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Not everything that counts can be counted, and not
everything that can be counted counts—Albert Einstein
Medicine is a science of uncertainty and an art of
probability—Sir William Osler
The past decade has witnessed revolution in biomedical
sciences, among them are the completion of human genome
projects and coming of age of the systems biology [1, 2].
Their impacts on medicine are continuously unraveling [1].
With the developments of high-throughput measurement
platforms, such as mass spectrometry (MS), and the next
generation DNA sequencing technology, we are now
capable of systematically categorizing almost all of the
biomolecules of humans in physiology and in illness. Many
candidate biomarkers potentially useful in early diagnosis,
prediction of natural history, and response to therapy have
been found even though their clinical usefulness remains to
be determined. Subsequently, it becomes clear that the
translation of the early success in biomarker discovery into
clinical practice is a much daunting task than most of us
have expected with validation a major hurdle.
Measurements are fundamental to scientific discovery in
which observation and data collection are the very first
steps. To ensure the reliable scientific inference, analytical,
statistical, and clinical validations are essential so that
clinical usefulness of the candidate biomarkers can be fully
understood. However, validation has been extremely
challenging in cancers and other complex human disease
alike. This is evident by the fact that few biomarkers have
been convincingly validated and approved for clinical use
despite tremendous efforts invested in recent years [3].
We are at the crossroad where validation is the barrier in
bringing these biomarkers into clinical use. The dilemma
we are facing is that there are too many candidate
biomarkers. We have to be highly selective with respect
to which biomarkers are potentially useful clinically. We
believe that we need in-depth understanding of the
information contents of the candidate biomarkers in order
for us to commit the limited resources to bring the effective
cancer biomarkers to patient care. We need to rethink the
rationales for biomarkers discovery and our working
assumptions on which successful validations will be
hinged.
The question is why biomarker validation is so difficult to
tackle under the current strategy for biomarker evaluation?
Serum biomarker discovery has been largely based on a
working assumption that the concentrations of biomole-
cules would be up- or down-regulated in illness compared
with the homeostasis of human physiology. For example,
we are searching for changes in serum concentration of
cancer biomarkers by comparing matching samples from
healthy and disease population. The study design usually
consisted of cases and controls or with a set of patient
samples at multiple time points. Vast amount of data in
clinical diagnostic devices have been collected in such
fashion. In addition, by default we also assume that there is
inherent information in the quantitative clinical observations,
even for data collected from the studies with poorly defined
study population. However, these assumptions may be
flawed. The heterogeneity of the study populations aside, it
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is arguable that the signaling derived from the up and down
movements of biomarkers may be merely indicative of early
stages of the disease spectrum. The up or down movements in
concentration of the target biomolecules is likely due to
feedback regulation of the system’s attempt to compensate for
the gain or loss of functions incurred by the underlying
pathophysiological changes. Such changes could be the result
of nucleotide structural variations from the accumulation of
somatic mutations, or other transient signaling events caused
by posttranslational modifications such as phosphorylation,
glycosylation, and others. Under these circumstances, the
quantitative signal is probably not pathological. In another
word, they are mostly physiological noises, which are not
robust, even irrelevant for disease marker discovery.
Complex human disease networks are composed of
many interconnecting pathways [4]. We believe that human
cancer is likely caused by constitutively activated signaling
pathways. However, these signaling pathways may not be
present in the same configuration as that in the homeostasis.
It is likely that the accumulated somatic mutations could
cause protein conformational or other subtle structural
changes leading to gradually decompensation of the
physiological functions of tissues or organs. The result of
these changes in protein folding patterns could facilitate the
aberrant protein–protein interactions in the vastly complex
disease networks. The conformation change could expose
novel antigenic determinants to the pattern recognition
receptors of the innate immunity triggering systemic
immune response and inflammatory reactions [5]. These
types of biomarkers are not differentiable by their mass values
as an upward or downward movement in concentration.
Furthermore, we should not assume that all serum
biomarkers carry equal amount of information as implied
by their intrinsic values. Information is the useful data
[6]. We should recognize that the data or observations do
not change with time but our interpretation could. For
example, with different binding partners, a candidate
biomarker may have different function. More importantly,
data needed to be interpreted in the context of the dynamic
process of disease development which requires integrating
all the temporal and spatial information from the biomarkers.
The usefulness of biomarkers is defined by the clinical
context. Therefore, understanding of the target population,
prevalence, and disease parameters of the target population is
vital for the validation. Biomarkers cannot be effectively
validated if the underlying clinical entity is not clearly
defined.
In biology, information flows from DNA to RNA and to
proteins. Proteins are the effectors of biological functions.
The protein folding patterns cannot be inferred by the
underlying DNA sequence. At the protein level, the
information is encoded in the corresponding variations in
amino acid sequence and modulated by an array of the
posttranslation modifications [7–9]. If a protein in its linear
form has no biological function, the information content
must be represented in the overall patterns of protein
folding. Disease phenotypes in humans could reflect the
loss of homeostasis at least in part by the changes in protein
conformation as demonstrated by many neurodegenerative
diseases. The relevance of the protein conformation to
cancer development is unknown largely because the
information represented by the variations in conformation
is not readily measurable and understood. If the data are
noninterpretable in clear biological languages, there is no
information associated with the data [10].
Currently, most of the clinical measurements are not
designed to capture the information presented in protein
conformation changes. The common practice in biomarker
validations of adopting an artificial cutoff threshold in the
quantitative assays to demarcate the “disease” from the
“non-disease” is problematic for effective biomarker validation.
Cancer involves probably stochastically connected aberrant
signaling pathways [11]. The protein conformation and
complex structures are complicated. The information
pertaining to disease status cannot be deduced reliably
from the data that have been reduced to two distinctive
subsets denoted as “Yes” and “No” (1 and 0) because
disease spectrum is a continuous process with progressive,
accumulative, and qualitative changes. Unless the popula-
tion distribution of the markers in disease and nondisease
is clearly bimodal with minimal overlap, the imposed
cutoff is intuitively counterproductive.
Cancer is a complex disease. Multiple cancer markers
are likely needed to delineate its pathophysiology and its
molecular phenotypes. This is especially true when the
complexity in human disease generates emerging phenotypes
at the systems level [12]. In this sense, there are probably no
perfect biomarkers if used alone, but with multiplexing, they
can contribute to incremental gain of information. In this
case, data processing with the cutoff threshold approach
could be too simplistic to be meaningful biologically and
clinically.
Diagnostics is playing increasingly important roles in
triage of different molecular subtypes of a cancer under a
common name to appropriate therapeutic regimens. In
clinical settings, effective and safe clinical measurements
are intended to answer a seemingly simple question; i.e.,
should the patient be treated? Validated and interpretable
signature biomarkers for the molecular phenotypes are in
great demands. Toward this goal, we should be mindful that
whether our assumptions about the illness are defensible,
and the rationales of biomarkers discovery are valid to
ensure the candidate biomarkers can be effectively decoded
for useful information.
It is necessary to explore the alternative approach in
biomarker discovery for unmet medical needs for actionable
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information. The variations in folding patterns of the
functional proteins such as enzymes and cell signaling
molecules like the interleukins and oncoproteins could offer
a new paradigm in identifying the candidate biomarkers for
the complex diseases that can be efficiently validated.
Technical advancement in measurements and thoughtful
interpretation of the information should allow the vision of
tailored treatment of personalized medicine within our reach
in the foreseeable future.
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